Presbia PLC (NASDAQ: LENS), an ophthalmic device company and leader in
near-vision restoration, announced today that Presbia will be
participating at the 30thCongress of Deutschsprachige
Gesellschaft für Intraokularlinsen-Implantation, Interventionelle und
Refraktive Chirurgie (DGII), to be held in Mannheim, Germany on February
11 through February 13, 2016. The DGII Congress is a gathering of
experts presenting the newest scientific research and trends in the area
of cataract and refractive surgery. Presbia board member Gerd U.
Auffarth, M.D., Ph.D., F.E.B.O. will conduct a presentation at the
"We are currently launching commercially in South Korea, and Germany is
an important market for Presbia's expansion in the next year. The DGII
Congress is an ideal forum to further showcase our innovative Presbia
Microlens™ and also expand the awareness of our groundbreaking treatment
for near-vision restoration for patients worldwide," said Todd Cooper,
President and CEO of Presbia.
Presbia's new Business Development Director for Europe, Volkmar Nass,
will be available for one-on-one meetings at the Congress.
This release contains "forward-looking statements" made pursuant to the
safe harbor provisions of the Private Securities Litigation Reform Act
of 1995. Information provided and statements contained in this press
release that are not purely historical are forward-looking statements.
Such forward-looking statements only speak as of the date of this press
release and Presbia assumes no obligation to update the information
included in this press release. Statements made in this press release
that are forward-looking in nature may involve risks and uncertainties,
including, but not limited to, the factors listed under "Risk Factors"
in our annual report on Form 10-K and quarterly reports on Form 10-Q.
Accordingly, readers are cautioned that any such forward-looking
statements are not guarantees and are subject to certain risks,
uncertainties and assumptions that are difficult to predict. Although
Presbia believes that the expectations reflected in such forward-looking
statements are reasonable as of the date made, expectations may prove to
have been materially different from the results expressed or implied by
such forward-looking statements. Unless otherwise required by law,
Presbia also disclaims any obligation to update its view of any such
risks or uncertainties or to announce publicly the result of any
revisions to the forward-looking statements made in this press release.
Presbia PLC (NASDAQ:LENS) is an ophthalmic device company that has
developed and is currently marketing the presbyopia-correcting Presbia
Flexivue Microlens™, a miniature lens that is implanted in a corneal
pocket created by a femtosecond laser. The Presbia Flexivue Microlens™
has received a CE mark for the European Economic Area, allowing the lens
to be marketed in over 30 countries across Europe. A staged pivotal U.S.
clinical trial for the Presbia Flexivue Microlens™ commenced in 2014.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160204005295/en/
Monica Yamada, 323-860-4903
Source: Presbia PLC
News Provided by Acquire Media